Ursula N.
- Country
- Germany
- Department
- Klinik für Strahlentherapie
Research Overview
- Evaluation of Durvalumab in Combination with Cisplatin, Carboplatin, and Etoposide with Radiotherapy in Extensive-Stage Small Cell Lung Cancer
- Evaluation of Morphologic Complete Response in Early Stage Nodal Follicular Lymphoma with Rituximab or Obinutuzumab Plus Radiotherapy
- Evaluation of Thoracic Radiotherapy and Durvalumab in Elderly/Frail Patients with Unresectable Stage III Non-Small Cell Lung Cancer Unfit for Chemotherapy
Data & Insights
Has run more than one trial at 15 of 52 partner sites.
Specializations
Lung Cancer Research
Specializes in advanced therapeutic approaches for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular focus on treating unresectable stage III cases.
- Combined immunotherapy and radiotherapy protocols
- FDG-PET-based treatment planning
- Thoracic radiotherapy optimization
Explores innovative treatment strategies for elderly and frail patients who are unsuitable for conventional chemotherapy.
Gastrointestinal Oncology
Focuses on treatment protocols for locally-advanced anal carcinoma, investigating combined modality approaches for stage IIB-IIIC cases.
- Radiochemotherapy combinations
- Immune checkpoint inhibition
- Disease-free survival optimization
Integrates modern imaging techniques including MRI and proctoscopy for treatment response assessment.
Hematologic Oncology
Conducts research in the treatment of early-stage follicular lymphoma, exploring various radiotherapy dosing strategies combined with targeted therapies.
- Involved site radiotherapy
- Anti-CD20 antibody treatments
- Response rate assessment
Evaluates both standard and low-dose radiation protocols in combination with novel antibody treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.